1. bookVolume 71 (2022): Issue 2 (June 2022)
Journal Details
License
Format
Journal
eISSN
2544-4646
First Published
04 Mar 1952
Publication timeframe
4 times per year
Languages
English
access type Open Access

Diminished Susceptibility to Cefoperazone/Sulbactam and Piperacillin/Tazobactam in Enterobacteriaceae Due to Narrow-Spectrum β-Lactamases as Well as Omp Mutation

Published Online: 19 Jun 2022
Volume & Issue: Volume 71 (2022) - Issue 2 (June 2022)
Page range: 251 - 256
Received: 08 Mar 2022
Accepted: 30 Apr 2022
Journal Details
License
Format
Journal
eISSN
2544-4646
First Published
04 Mar 1952
Publication timeframe
4 times per year
Languages
English
Abstract

Cefoperazone/sulbactam (CSL) and piperacillin/tazobactam (TZP) are commonly used in clinical practice in China because of their excellent antimicrobial activity. CSL and TZP-nonsusceptible Enterobacteriaceae are typically resistant to extended-spectrum cephalosporins such as ceftriaxone (CRO). However, 11 nonrepetitive Enterobacteriaceae strains, which were resistant to CSL and TZP yet susceptible to CRO, were collected from January to December 2020. Antibiotic susceptibility tests and whole-genome sequencing were conducted to elucidate the mechanism for this rare phenotype. Antibiotic susceptibility tests showed that all isolates were amoxicillin/clavulanic-acid resistant and sensitive to ceftazidime, cefepime, cefepime/tazobactam, cefepime/zidebactam, ceftazidime/avibactam, and ceftolozane/tazobactam. Whole-genome sequencing revealed three of seven Klebsiella pneumoniae strains harbored blaSHV-1 only, and four harbored blaSHV-1 and blaTEM-1B. Two Escherichia coli strains carried blaTEM-1B only, while two Klebsiella oxytoca isolates harbored blaOXY-1-3 and blaOXY-1-1, respectively. No mutation in the β-lactamase gene and promoter sequence was found. Outer membrane protein (Omp) gene detection revealed that numerous missense mutations of OmpK36 and OmpK37 were found in all strains of K. pneumoniae. Numerous missense mutations of OmpK36 and OmpK35 and OmpK37 deficiency were found in one K. oxytoca strain, and no OmpK gene was found in the other. No Omp mutations were found in E. coli isolates. These results indicated that narrow spectrum β-lactamases, TEM-1, SHV-1, and OXY-1, alone or in combination with Omp mutation, contributed to the resistance to CSL and TZP in CRO-susceptible Enterobacteriaceae.

Antibiotic susceptibility tests

Antibiotics Breakpoint, (μg/ml) Klebsiella pneumoniae
Escherichia cou
Klebriehd axyoca
E1 E3 E4 E7 E9 E10 E11 E6 E8 E2 E5
CRO ≤1≥4 ≤0.5 ≤0.5 ≤0.5 ≤0.5 1 ≤0.5 1 ≤0.5 ≤0.5 1 1
CAZ 4 ≥16 1 2 1 4 4 4 4 2 4 1 1
FEP ≤2 216 1 1 0.25 1 2 2 2 0.5 2 1 1
AMC ≤8 ≥32 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128
CSL ≤16 ≥64 64 64 64 64 ≥128 128 ≥128 64 128 128 ≥128
TZP ≤16 ≥128 ≥256 ≥256 ≥256 ≥256 2256 2256 ≥256 ≥256 ≥256 ≥256 ≥256
FPT ≤2 ≥16 1 0.5 0.06 0.125 2 1 2 0.25 1 0.125 0.25
FPZ ≤2 216 0.25 0.25 0.06 0.125 0.25 0.25 1 0.125 0.25 0.125 0.125
CZA ≤8 216 1 0.5 0.25 0.25 1 0.25 1 0.5 0.5 0.5 0.25
CZT ≤2 28 2 1 0.5 1 2 2 2 1 1 2 2

CROceftriaxone, CAZceftazidime, FEPcefepime, AMC:amoxicillin clavulanic-acid, CSLcefoperazone/sulbactam, TZP:piperadllin/tazobactam, FPT:cefepime tazobactam, FPZ:cefepime/zidebactam, CZA:ceftazidime/avibactam, CZTceftolozane/tazobactam

Gene sequencing results

Number Strain ST p-Lactamase gene Promoter sequence mutation Omp mutation
El Kpn 45 blaSHV-1, blaTEM-lB none OmpK36, OmpK3 7
E3 Kpn 45 blaSHV-1, blaTEM-lB none OmpK36. OmpK3 7
E4 Kpn 2854 blaSHV-1 none OmpK36, OmpK3 7
E7 Kpn 2358 blaSHV-1 - blaTEM-lB none OmpK36, OmpK3 7
E9 Kpn 2358 blaSHV-1. blaTEM-lB none OmpK36. OmpK3 7
E10 Kpn 18 9 blaSHV-1 none OmpK36. OmpK3 7
Ell Kpn 45 blaSHV-1 none OmpK36, OmpK3 7
E6 Eco 88 blaTEM-lB none none
ES Eco 409 blaTEM-1B none none
E2 Kox 194 blaOXY-1-3 none OmpK36 mutations. OmpK35 and OmpK 37 deficiency
E5 Kox 11 blaOXY-1-1 none no OmpK (OmpK3 5, OmpK36 and OmpK37) gene found

Keywords

Introduction

Enterobacteriaceae, such as Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca, are responsible for approximately 30% of healthcare-associated infections (Stewart et al. 2021). The antibiotics cefoperazone/sulbactam (CSL) and piperacillin/tazobactam (TZP) have broad activity spectra against Gram-positive, Gram-negative, and anaerobic organisms. In China, CSL and TZP are widely used in daily clinical practice (Chen et al. 2021). However, a decreasing rate of susceptibility to CSL and TZP among Enterobacteriaceae threatens their continued use. Enzymes such as carbapenemases, AmpC β-lactamase, and some extended-spectrum β-lactamases (ESBLs) (Stewart et al. 2021), are the leading cause of CSL and TZP-resistant Enterobacteriaceae isolates. Many of these enzymes also hydrolyze third-generation cephalosporins and most CSL and TZP-nonsusceptible Enterobacteriaceae are also resistant to ceftriaxone (CRO). We recently encountered Enterobacteriaceae isolates that were CSL and TZP-resistant (R), but CRO-susceptible (S). Here, antibiotic susceptibility tests and the whole genome-sequencing technique were applied to explore their resistance mechanisms.

Experimental
Materials and Methods

Bacterial isolates. This retrospective study was conducted from January to December 2020 in the Department of Laboratory Medicine, Yantai Yuhuangding Hospital of Shandong Province, a 3,000-bed tertiary teaching hospital located in east China. Enterobacteriaceae strains resistant to CSL and TZP but sensitive to CRO were collected in routine clinical practice. All isolates intentionally collected for this study were cultured in blood agar in a 35°C incubator for 16–24 hours and then stored in skim milk in a deep freezer at –80°C until use. Duplicate isolates collected from the same patient within three months were excluded. The patients’ medical records were retrospectively reviewed, and information on clinical characteristics, including age, sex, and source of infection, was collected. Approval and verbal informed consent were obtained for experimentation with human subjects due to the study’s retrospective nature. The study protocol, including the verbally informed consent procedure, was approved by the Yantai Yuhuangding Hospital Ethics Committee.

Identification and antibiotic susceptibility tests. All isolates were initially identified with the VITEK®2 GN card (bioMérieux, France). Then, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Bruker Daltonics, Germany) was used to confirm the identification. All procedures were performed following the manufacturer’s instructions. According to the Clinical Laboratory Standards Institute (CLSI) guidelines, the minimum inhibitory concentrations (MICs) of TZP (4−128 μg/ml) and ceftazidime (CAZ, 1−64 μg/ml) were determined by VITEK®2 AST-GN09 card (bioMérieux, France). CSL resistance was tested by the disk diffusion method on Mueller-Hinton agar (105 μg, Oxoid, UK) and then confirmed by the broth microdilution method (1–128 μg/ml, Thermo Fisher Scientific, USA). The MICs of CRO (0.5–32 μg/ml), cefepime (FEP, 0.06–128 μg/ml), amoxicillin/clavulanic acid (AMC, 0.06–128 μg/ml), cefepime/tazobactam (FPT, 0.03–64 μg/ml), cefepime/zidebactam (FPZ, 0.03−64 μg/ml), ceftazidime/avibactam (CZA, 0.03−64 μg/ml) and ceftolozane/tazobactam (CZT, 0.06−128 μg/ml) were determined by the broth microdilution method (Thermo Fisher Scientific, USA), according to the CLSI. The MIC breakpoints were interpreted according to the CLSI document M100-S30 (CLSI 2020). E. coli ATCC 25922 was used as a control in antibiotic-susceptibility tests.

Genome sequencing. Genomic DNA was extracted using a Genomic DNA kit (Tiangen, DP305). DNA concentration was quantified using a NanoDropTM 2000 (Thermo Scientific, USA) spectrophotometer, and verified by agarose gel electrophoresis. Fifty ng of the extracted DNA extracted was required for library preparation. Libraries were prepared using the TruePrepTM DNA Library Prep Kit V2 for Illumina (Vazyme). The sample’s DNA was simultaneously fragmented and tagged with adapters in a single “transposase” enzymatic reaction. An optimized, limited-cycle polymerase chain reaction (PCR) protocol amplified tagged DNA and added sequencing indexes. Individual libraries were assessed on the QIAxcel Advanced Automatic nucleic acid analyzer and then quantitated through quantitative real-time PCR (qPCR) using KAPA SYBR® FAST qPCR kits. Finally, the library was sequenced on an Illumina HiSeq 2500 sequencing platform (Illumina Inc., USA), and 150 bp paired-end reads were generated. Raw data were filtered to remove low-quality reads, and then clean data were assembled via SPAdes v3.13. All sequencing data were uploaded to the National Center for Biotechnology Information (NCBI) database (https://submit.ncbi.nlm.nih.gov). The β-lactamase genes and outer membrane protein (Omp) genes and mutations were identified by BLAST using the ResFinder 3.0 (https://cge.cbs.dtu.dk/services/ResFinder/) via thresholds of 90% identity and minimum length coverage of 60%. The sequence type (ST) was performed using MLST 2.0 (https://cge.cbs.dtu.dk/services/MLST/). The promoter sequence of the β-lactamase gene was annotated with a Promoter 2.0 software and compared via BLAST (https://blast.ncbi.nlm.nih.gov/Blast.cgi).

Results

Identification and clinical characteristics. According to the inclusion criteria, 11 nonrepetitive strains were enrolled, including seven cases of K. pneumoniae, two cases of E. coli, and two cases of K. oxytoca. Among the 11 strains, five were isolated from sputum, three from urine, and one from bile, pus and blood, respectively. Fifty-five percent (6/11) of the isolates were obtained from an intensive care unit, 18% (2/11) from a neurosurgery ward, and 9% (1/11) from a stomatological ward, vascular surgery ward, and hepatobiliary ward, respectively. The age of the patients ranged from 41 to 91-years-old, with an average of 67.64 ± 15.27-years-old, of which 45% (5/11) were male and 55% (6/11) were female.

Antibiotic susceptibility tests. The results of antibiotic susceptibility tests are shown in Table I. In addition to CRO, CSL, and TZP as inclusion criteria, the antibacterial activities of CAZ, FEP, and currently available β-lactam/β-lactamase inhibitors (BL/BLIs), including AMC, FPT, FPZ, CZA, and CZT were also assayed. As shown in Table I, all isolates were susceptible to CRO, CAZ, and FEP, and MIC90 were 1, 4, and 2 μg/ml, respectively. All strains were resistant to AMC, CSL, and TZP with the MIC90 ≥ 128, ≥ 128, and ≥ 256 μg/ml, respectively. Moreover, these strains showed sensitivity to FPT, FPZ, CZA, and CZT, and the MIC90 were 2, 0.25, 1, and 2 μg/ml, respectively.

Antibiotic susceptibility tests by CLSI micro broth dilution method.

Antibiotics Breakpoints (μg/ml) Klebsiella pneumoniae Escherichia coli Klebsiella oxytoca
E1 E3 E4 E7 E9 E10 E11 E6 E8 E2 E5
CRO ≤ 1 ≥ 4 ≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 1 ≤ 0.5 1 ≤ 0.5 ≤ 0.5 1 1
CAZ ≤ 4 ≥ 16 1 2 1 4 4 4 4 2 4 1 1
FEP ≤ 2 ≥ 16 1 1 0.25 1 2 2 2 0.5 2 1 1
AMC ≤ 8 ≥ 32 ≥ 128 ≥ 128 ≥ 128 ≥ 128 ≥ 128 ≥ 128 ≥ 128 ≥ 128 ≥ 128 ≥ 128 ≥ 128
CSL ≤ 16 ≥ 64 64 64 64 64 ≥ 128 128 ≥ 128 64 128 128 ≥ 128
TZP ≤ 16 ≥ 128 ≥ 256 ≥ 256 ≥ 256 ≥ 256 ≥ 256 ≥ 256 ≥ 256 ≥ 256 ≥ 256 ≥ 256 ≥ 256
FPT ≤ 2 ≥ 16 1 0.5 0.06 0.125 2 1 2 0.25 1 0.125 0.25
FPZ ≤ 2 ≥ 16 0.25 0.25 0.06 0.125 0.25 0.25 1 0.125 0.25 0.125 0.125
CZA ≤ 8 ≥ 16 1 0.5 0.25 0.25 1 0.25 1 0.5 0.5 0.5 0.25
CZT ≤ 2 ≥ 8 2 1 0.5 1 2 2 2 1 1 2 2

CRO – ceftriaxone, CAZ – ceftazidime, FEP – cefepime, AMC – amoxicillin/clavulanic-acid, CSL – cefoperazone/sulbactam,

TZP – piperacillin/tazobactam, FPT – cefepime/tazobactam, FPZ – cefepime/zidebactam, CZA – ceftazidime/avibactam,

CZT – ceftolozane/tazobactam

Genome sequencing. The results of gene sequencing are listed in Table II. No dominant ST was found. ST45 accounted for 42.8% (n = 3) of K. pneumoniae, followed by ST2358, ST2854, and ST189. The sequence types of E. coli were ST88 and ST409. The sequence types of K. oxytoca were ST194 and ST11. Three of the seven K. pneumoniae strains harbored blaSHV-1 while four carried blaSHV-1 and blaTEM-1B. All strains of E. coli had the blaTEM-1B gene. One K. oxytoca isolate carried blaOXY-1-3, and the other harbored blaOXY-1-1. No mutation in the β-lactamase gene and promoter sequence was found. None of the isolates possessed an ESBL enzyme, AmpC β-lactamase, or carbapenemase. Numerous missense mutations of OmpK36 and OmpK37 were found in all strains of K. pneumoniae, while no OmpK35 mutation was found. Numerous missense mutations of OmpK36 and OmpK35 and OmpK37 genes deficiency were found in one K. oxytoca strain, and no OmpK gene was found in the other. No Omp (OmpC or OmpF) point mutation was found in E. coli isolates.

Gene sequencing results.

Number Accession Strain ST β-Lactamase gene Promoter sequence mutation Omp mutation
E1 JAKQYI000000000 Kpn 45 blaSHV-1, blaTEM-1B none OmpK36, OmpK37
E3 JAKOEX000000000 Kpn 45 blaSHV-1, blaTEM-1B none OmpK36, OmpK37
E4 JAKOEY000000000 Kpn 2854 blaSHV-1 none OmpK36, OmpK37
E7 JAKOGA000000000 Kpn 2358 blaSHV-1, blaTEM-1B none OmpK36, OmpK37
E9 JAKOGC000000000 Kpn 2358 blaSHV-1, blaTEM-1B none OmpK36, OmpK37
E10 JAKOGD000000000 Kpn 189 blaSHV-1 none OmpK36, OmpK37
E11 JAKOPO000000000 Kpn 45 blaSHV-1 none OmpK36, OmpK37
E6 JAKOEZ000000000 Eco 88 blaTEM-1B none none
E8 JAKOGB000000000 Eco 409 blaTEM-1B none none
E2 JAKPCC000000000 Kox 194 blaOXY-1-3 none OmpK36 mutations, OmpK35 and OmpK37 deficiency
E5 JAKPCD000000000 Kox 11 blaOXY-1-1 none no OmpK (OmpK35, OmpK36 and OmpK37) gene found

KpnKlebsiella pneumoniae, Eco – Escherichia coli, KoxKlebsiella oxytoca

Discussion

In recent years, the global research on β-lactamases has been focused mainly on ESBLs, AmpC β-lactamase, and carbapenemase, while some narrow-spectrum β-lactamases have been ignored. It has resulted in clinical treatment failures. In this study, none of these isolates harbored an ESBL, AmpC β-lactamase, or carbapenemase. There have been few published analyses of Enterobacteriaceae displaying a CSL-R/TZP-R/CRO-S resistance phenotype. It is increasingly urgent to understand the CSL/TZP-resistance due to the emergence of a CSL/TZP-resistant but 3rd generation cephalosporin-susceptible Enterobacteriaceae phenotype, as well as the increasing reliance on CSL and TZP as empirical treatments in daily clinical practice in China.

TEM-1, SHV-1, and OXY-1 β-lactamases are narrow-spectrum β-lactamases, which belong to group 2be in the Bush-Jacoby classification scheme (Pater-son and Bonomo 2005; Kashefieh et al. 2021; Rehman et al. 2021). Enterobacteriaceae with TEM-1, SHV-1, or OXY-1 β-lactamase are usually susceptible to CSL and TZP. However, Enterobacteriaceae strains resistant to CSL and TZP yet susceptible to CRO were observed in this study. It is reported that the gene mutation-induced single amino acid substitutions at Ambler positions Met69, Ser130, Arg244, Arg275, and Asp276 in TEM and SHV β-lactamases may result in enzymes with reduced affinity for β-lactamase inhibitors (Ramdani-Bouguessa et al. 2011; Winkler et al. 2015). Another possible mechanism is that resistance to BL/BLIs may result from gene amplification, and subsequent hyperproduction of β-lactamase (Sun et al. 2013; Noguchi et al. 2019; Zhou et al. 2019; Hubbard et al. 2020). Mutations in the promoters have been shown to be responsible for blaOXY-1 and blaSHV-1 amplification (Fournier et al. 1999; Han et al. 2020). Moreover, a strong promoter, such as the Pa/ Pb promoter or IS26-mediated excision and repeated insertion can also lead to the TEM-1 hyperproduction (Noguchi et al. 2019; Hubbard et al. 2020). Exposure to BL/BLIs such as TZP has been shown to induce the excision and repeated insertion of bla TEM‑1, increase the blaTEM-1 copy number and then lead to the TEM-1 hyperproduction (Schechter et al. 2018). No mutation in the β-lactamase gene and promoter sequence was found in this study. It is speculated that the possible mechanism of resistance to CSL and TZP is the gene amplification caused by gene excision and repeated insertion. The emergence of multiple β-lactamase gene copies in genome sequence and the wide application of CSL and TZP in China support this hypothesis.

Omp is necessary for drug transport across cell membranes. A deficiency of Omp has been shown to contribute to the increase in the MIC for Enterobacteriaceae (Aihara et al. 2021). The current research on Omp focuses mainly on carbapenem-resistant Enterobacteriaceae (Tian et al. 2020), and few studies on Enterobacteriaceae with bla TEM-1B, bla SHV-1, or bla OXY-1 appear to have examined the prevalence of the Omp deficiency. OmpK is expressed in Klebsiella, and OmpK35 defects are common in isolates carrying genes encoding ESBL, while defects in OmpK36 may be more critical for carbapenem resistance (Martínez-Martínez 2008). The importance of the minor porin, OmpK37, is less clear. Except for one strain with the OmpK gene deficiency, numerous missense mutations in the porin genes OmpK36 and OmpK37 were found in almost all Klebsiella strains in our study. It may lead to non-functional porins and be associated with CSL and TZP resistance. OmpF and OmpC constitute the main Omps in E. coli (Bafna et al. 2020). No Omp mutation suggests that Omp is unnecessary for resistance against CSL and TZP in E. coli.

Another finding was that, although this collection of Enterobacteriaceae was resistant to AMC, CSL, or TZP, the newer BL/BLI combinations, FPT, FPZ, CZA, and CZT, were much more active. Previous studies have confirmed that the newer BL/BLI combinations exhibit excellent antibacterial activity against Enterobacteriaceae, consistent with this study (Joshi et al. 2021; Kuo et al. 2021). In addition, simultaneous analysis of the MICs of FEP, FPT, and FPZ delineated tazobactam as a distinctly less active inhibitor than zidebactam against strains producing TEM-1, SHV-1, and OXY-1 β-lactamases. It may be attributed to the dual activity of zidebactam, which can protect cefepime from hydrolysis by β-lactamases, but also bind the Gram-negative PBP2 and retain an excellent antibacterial activity (Thomson et al. 2019; Morroni et al. 2021).

This report presents the resistance to CSL and TZP in clinical isolates of Enterobacteriaceae possessing β-lactamases that were previously thought to be adequately inhibited by sulbactam and tazobactam. The high frequency of blaTEM-1, blaSHV-1, and blaOXY-1 in the CSL and TZP-resistant isolates supported the notion that blaTEM-1, blaSHV-1, and blaOXY-1, alone or in combination with Omp mutations, were important contributors to CSL and TZP resistance. However, some limitations existed in this study. We sequenced the whole genome of the collected strains, but we did not determine the activities of β-lactamases and the Omp expression. The transferability of β-lactamase genes was not confirmed. Other characteristics, such as efflux pumps or the permeation of CSL and TZP, were not evaluated. Thus, much more work is needed to clarify the resistance mechanisms of CSL/TZP-R but CRO-S Enterobacteriaceae.

Conclusion

In China, the CSL/TZP-R but CRO-S phenotype of Enterobacteriaceae is prevalent and threatens the optimal use of CSL and TZP. TEM-1, SHV-1, and OXY-1, the most common β-lactamases, alone or in combination with Omp mutations, contribute to the resistance of CSL and TZP. Continuous monitoring and investigation of CSL/TZP-R but CRO-S isolates are needed in the current era of high CSL and TZP administration.

Antibiotic susceptibility tests

Antibiotics Breakpoint, (μg/ml) Klebsiella pneumoniae
Escherichia cou
Klebriehd axyoca
E1 E3 E4 E7 E9 E10 E11 E6 E8 E2 E5
CRO ≤1≥4 ≤0.5 ≤0.5 ≤0.5 ≤0.5 1 ≤0.5 1 ≤0.5 ≤0.5 1 1
CAZ 4 ≥16 1 2 1 4 4 4 4 2 4 1 1
FEP ≤2 216 1 1 0.25 1 2 2 2 0.5 2 1 1
AMC ≤8 ≥32 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128 ≥128
CSL ≤16 ≥64 64 64 64 64 ≥128 128 ≥128 64 128 128 ≥128
TZP ≤16 ≥128 ≥256 ≥256 ≥256 ≥256 2256 2256 ≥256 ≥256 ≥256 ≥256 ≥256
FPT ≤2 ≥16 1 0.5 0.06 0.125 2 1 2 0.25 1 0.125 0.25
FPZ ≤2 216 0.25 0.25 0.06 0.125 0.25 0.25 1 0.125 0.25 0.125 0.125
CZA ≤8 216 1 0.5 0.25 0.25 1 0.25 1 0.5 0.5 0.5 0.25
CZT ≤2 28 2 1 0.5 1 2 2 2 1 1 2 2

Gene sequencing results.

Number Accession Strain ST β-Lactamase gene Promoter sequence mutation Omp mutation
E1 JAKQYI000000000 Kpn 45 blaSHV-1, blaTEM-1B none OmpK36, OmpK37
E3 JAKOEX000000000 Kpn 45 blaSHV-1, blaTEM-1B none OmpK36, OmpK37
E4 JAKOEY000000000 Kpn 2854 blaSHV-1 none OmpK36, OmpK37
E7 JAKOGA000000000 Kpn 2358 blaSHV-1, blaTEM-1B none OmpK36, OmpK37
E9 JAKOGC000000000 Kpn 2358 blaSHV-1, blaTEM-1B none OmpK36, OmpK37
E10 JAKOGD000000000 Kpn 189 blaSHV-1 none OmpK36, OmpK37
E11 JAKOPO000000000 Kpn 45 blaSHV-1 none OmpK36, OmpK37
E6 JAKOEZ000000000 Eco 88 blaTEM-1B none none
E8 JAKOGB000000000 Eco 409 blaTEM-1B none none
E2 JAKPCC000000000 Kox 194 blaOXY-1-3 none OmpK36 mutations, OmpK35 and OmpK37 deficiency
E5 JAKPCD000000000 Kox 11 blaOXY-1-1 none no OmpK (OmpK35, OmpK36 and OmpK37) gene found

Antibiotic susceptibility tests by CLSI micro broth dilution method.

Antibiotics Breakpoints (μg/ml) Klebsiella pneumoniae Escherichia coli Klebsiella oxytoca
E1 E3 E4 E7 E9 E10 E11 E6 E8 E2 E5
CRO ≤ 1 ≥ 4 ≤ 0.5 ≤ 0.5 ≤ 0.5 ≤ 0.5 1 ≤ 0.5 1 ≤ 0.5 ≤ 0.5 1 1
CAZ ≤ 4 ≥ 16 1 2 1 4 4 4 4 2 4 1 1
FEP ≤ 2 ≥ 16 1 1 0.25 1 2 2 2 0.5 2 1 1
AMC ≤ 8 ≥ 32 ≥ 128 ≥ 128 ≥ 128 ≥ 128 ≥ 128 ≥ 128 ≥ 128 ≥ 128 ≥ 128 ≥ 128 ≥ 128
CSL ≤ 16 ≥ 64 64 64 64 64 ≥ 128 128 ≥ 128 64 128 128 ≥ 128
TZP ≤ 16 ≥ 128 ≥ 256 ≥ 256 ≥ 256 ≥ 256 ≥ 256 ≥ 256 ≥ 256 ≥ 256 ≥ 256 ≥ 256 ≥ 256
FPT ≤ 2 ≥ 16 1 0.5 0.06 0.125 2 1 2 0.25 1 0.125 0.25
FPZ ≤ 2 ≥ 16 0.25 0.25 0.06 0.125 0.25 0.25 1 0.125 0.25 0.125 0.125
CZA ≤ 8 ≥ 16 1 0.5 0.25 0.25 1 0.25 1 0.5 0.5 0.5 0.25
CZT ≤ 2 ≥ 8 2 1 0.5 1 2 2 2 1 1 2 2

Gene sequencing results

Number Strain ST p-Lactamase gene Promoter sequence mutation Omp mutation
El Kpn 45 blaSHV-1, blaTEM-lB none OmpK36, OmpK3 7
E3 Kpn 45 blaSHV-1, blaTEM-lB none OmpK36. OmpK3 7
E4 Kpn 2854 blaSHV-1 none OmpK36, OmpK3 7
E7 Kpn 2358 blaSHV-1 - blaTEM-lB none OmpK36, OmpK3 7
E9 Kpn 2358 blaSHV-1. blaTEM-lB none OmpK36. OmpK3 7
E10 Kpn 18 9 blaSHV-1 none OmpK36. OmpK3 7
Ell Kpn 45 blaSHV-1 none OmpK36, OmpK3 7
E6 Eco 88 blaTEM-lB none none
ES Eco 409 blaTEM-1B none none
E2 Kox 194 blaOXY-1-3 none OmpK36 mutations. OmpK35 and OmpK 37 deficiency
E5 Kox 11 blaOXY-1-1 none no OmpK (OmpK3 5, OmpK36 and OmpK37) gene found

Aihara M, Nishida R, Akimoto M, Gotoh Y, Kiyosuke M, Uchiumi T, Nishioka M, Matsushima Y, Hayashi T, Kang D. Within-host evolution of a Klebsiella pneumoniae clone: selected mutations associated with the alteration of outer membrane protein expression conferred multidrug resistance. J Antimicrob Chem-other. 2021 Jan 19;76(2):362–369. https://doi.org/10.1093/jac/dkaa439 Aihara M Nishida R Akimoto M Gotoh Y Kiyosuke M Uchiumi T Nishioka M Matsushima Y Hayashi T Kang D Within-host evolution of a Klebsiella pneumoniae clone: selected mutations associated with the alteration of outer membrane protein expression conferred multidrug resistance J Antimicrob Chem-other 2021 Jan 1976 2 362 369 https://doi.org/10.1093/jac/dkaa43933099622Open DOISearch in Google Scholar

Bafna JA, Sans-Serramitjana E, Acosta-Gutiérrez S, Bodrenko IV, Hörömpöli D, Berscheid A, Brötz-Oesterhelt H, Winterhalter M, Ceccarelli M. Kanamycin uptake into Escherichia coli is facilitated by OmpF and OmpC porin channels located in the outer membrane. ACS Infect Dis. 2020 Jul 10;6(7):1855–1865. https://doi.org/10.1021/acsinfecdis.0c00102 Bafna JA Sans-Serramitjana E Acosta-Gutiérrez S Bodrenko IV Hörömpöli D Berscheid A Brötz-Oesterhelt H Winterhalter M Ceccarelli M Kanamycin uptake into Escherichia coli is facilitated by OmpF and OmpC porin channels located in the outer membrane ACS Infect Dis 2020 Jul 106 7 1855 1865 https://doi.org/10.1021/acsinfecdis.0c0010232369342Open DOISearch in Google Scholar

Chen Y, Xiang Q, Liu L. Comparison of antibiotic-associated diarrhea caused by cefoperazone/sulbactam or piperacillin/tazobactam in neurosurgery patients. J Int Med Res. 2021 May;49(5): 3000605211019661. https://doi.org/10.1177/03000605211019661 Chen Y Xiang Q Liu L Comparison of antibiotic-associated diarrhea caused by cefoperazone/sulbactam or piperacillin/tazobactam in neurosurgery patients J Int Med Res 2021 May49 5 3000605211019661 https://doi.org/10.1177/03000605211019661817029634057835Open DOISearch in Google Scholar

CLSI. Performance standards for antimicrobial susceptibility testing. 30th ed. CLSI supplement M100. Wayne (USA): Clinical and Laboratory Standards Institute; 2020. CLSI Performance standards for antimicrobial susceptibility testing. 30th ed. CLSI supplement M100 Wayne (USA) Clinical and Laboratory Standards Institute 2020Search in Google Scholar

Fournier B, Gravel A, Hooper DC, Roy PH. Strength and regulation of the different promoters for chromosomal beta-lactamases of Klebsiella oxytoca. Antimicrob Agents Chemother. 1999 Apr; 43(4): 850–855. https://doi.org/10.1128/AAC.43.4.850 Fournier B Gravel A Hooper DC Roy PH Strength and regulation of the different promoters for chromosomal beta-lactamases of Klebsiella oxytoca Antimicrob Agents Chemother 1999 Apr43 4 850 855 https://doi.org/10.1128/AAC.43.4.8508921610103190Open DOISearch in Google Scholar

Han MS, Park KS, Jeon JH, Lee JK, Lee JH, Choi EH, Lee SH. SHV Hyperproduction as a mechanism for piperacillin-tazobactam resistance in extended-spectrum cephalosporin-susceptible Klebsiella pneumoniae. Microb Drug Resist. 2020 Apr;26(4):334–340. https://doi.org/10.1089/mdr.2019.0079 Han MS Park KS Jeon JH Lee JK Lee JH Choi EH Lee SH SHV Hyperproduction as a mechanism for piperacillin-tazobactam resistance in extended-spectrum cephalosporin-susceptible Klebsiella pneumoniae Microb Drug Resist 2020 Apr26 4 334 340 https://doi.org/10.1089/mdr.2019.007931651221Open DOISearch in Google Scholar

Hubbard ATM, Mason J, Roberts P, Parry CM, Corless C, van Aartsen J, Howard A, Bulgasim I, Fraser AJ, Adams ER, et al. Piperacillin/tazobactam resistance in a clinical isolate of Escherichia coli due to IS26-mediated amplification of blaTEM-1B. Nat Commun. 2020 Oct 1;11(1):4915. https://doi.org/10.1038/s41467-020-18668-2 Hubbard ATM Mason J Roberts P Parry CM Corless C van Aartsen J Howard A Bulgasim I Fraser AJ Adams ER et al Piperacillin/tazobactam resistance in a clinical isolate of Escherichia coli due to IS26-mediated amplification of blaTEM-1B Nat Commun 2020 Oct 111 1 4915 https://doi.org/10.1038/s41467-020-18668-2753076233004811Open DOISearch in Google Scholar

Joshi P, Shrivastava R, Bhagwat S, Patel M. Activity of β-lactam plus β-lactam-enhancer combination cefepime/zidebactam against Klebsiella pneumoniae harbouring defective OmpK35/36 porins and carbapenemases. Diagn Microbiol Infect Dis. 2021 Oct;101(2):115481. https://doi.org/10.1016/j.diagmicrobio.2021.115481 Joshi P Shrivastava R Bhagwat S Patel M Activity of β-lactam plus β-lactam-enhancer combination cefepime/zidebactam against Klebsiella pneumoniae harbouring defective OmpK35/36 porins and carbapenemases Diagn Microbiol Infect Dis 2021 Oct101 2 115481 https://doi.org/10.1016/j.diagmicrobio.2021.11548134332307Open DOISearch in Google Scholar

Kashefieh M, Hosainzadegan H, Baghbanijavid S, Ghotaslou R. The molecular epidemiology of resistance to antibiotics among Klebsiella pneumoniae isolates in Azerbaijan, Iran. J Trop Med. 2021 Jul 12;2021:9195184. https://doi.org/10.1155/2021/9195184 Kashefieh M Hosainzadegan H Baghbanijavid S Ghotaslou R The molecular epidemiology of resistance to antibiotics among Klebsiella pneumoniae isolates in Azerbaijan, Iran J Trop Med 2021 Jul 1220219195184 https://doi.org/10.1155/2021/9195184829496434335793Open DOISearch in Google Scholar

Kuo SC, Wang YC, Tan MC, Huang WC, Shiau YR, Wang HY, Lai JF, Huang IW, Lauderdale TL. In vitro activity of imipenem/ relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan. J Antimicrob Chemother. 2021 Jul 15;76(8):2071–2078. https://doi.org/10.1093/jac/dkab141 Kuo SC Wang YC Tan MC Huang WC Shiau YR Wang HY Lai JF Huang IW Lauderdale TL In vitro activity of imipenem/ relebactam, meropenem/vaborbactam, ceftazidime/avibactam, cefepime/zidebactam and other novel antibiotics against imipenem-non-susceptible Gram-negative bacilli from Taiwan J Antimicrob Chemother 2021 Jul 1576 8 2071 2078 https://doi.org/10.1093/jac/dkab141856126533956969Open DOISearch in Google Scholar

Martínez-Martínez L. Extended-spectrum beta-lactamases and the permeability barrier. Clin Microbiol Infect. 2008 Jan;14(Suppl 1): 82–89. https://doi.org/10.1111/j.1469-0691.2007.01860.x Martínez-Martínez L. Extended-spectrum beta-lactamases and the permeability barrier Clin Microbiol Infect 2008 Jan14 Suppl 1 82 89 https://doi.org/10.1111/j.1469-0691.2007.01860.x18154531Open DOISearch in Google Scholar

Morroni G, Bressan R, Fioriti S, D’Achille G, Mingoia M, Cirioni O, Di Bella S, Piazza A, Comandatore F, Mauri C, et al. Antimicrobial activity of aztreonam in combination with old and new β-lactamase inhibitors against MBL and ESBL co-producing Gram-Negative clinical isolates: possible options for the treatment of complicated infections. Antibiotics (Basel). 2021 Nov 3;10(11):1341. https://doi.org/10.3390/antibiotics10111341 Morroni G Bressan R Fioriti S D’Achille G Mingoia M Cirioni O Di Bella S Piazza A Comandatore F Mauri C et al Antimicrobial activity of aztreonam in combination with old and new β-lactamase inhibitors against MBL and ESBL co-producing Gram-Negative clinical isolates: possible options for the treatment of complicated infections Antibiotics (Basel) 2021 Nov 310 11 1341 https://doi.org/10.3390/antibiotics10111341861500034827279Open DOISearch in Google Scholar

Noguchi T, Matsumura Y, Kanahashi T, Tanaka M, Tsuchido Y, Matsumura T, Nakano S, Yamamoto M, Nagao M, Ichiyama S. Role of TEM-1 β-lactamase in the predominance of ampicillin-sulbactam-nonsusceptible Escherichia coli in Japan. Antimicrob Agents Chemother. 2019 Jan 29;63(2):e02366-18. https://doi.org/10.1128/AAC.02366-18 Noguchi T Matsumura Y Kanahashi T Tanaka M Tsuchido Y Matsumura T Nakano S Yamamoto M Nagao M Ichiyama S Role of TEM-1 β-lactamase in the predominance of ampicillin-sulbactam-nonsusceptible Escherichia coli in Japan Antimicrob Agents Chemother 2019 Jan 2963 2 e02366 18 https://doi.org/10.1128/AAC.02366-18635557230455244Open DOISearch in Google Scholar

Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: A clinical update. Clin Microbiol Rev. 2005 Oct;18(4):657–686. https://doi.org/10.1128/CMR.18.4.657-686.2005 Paterson DL Bonomo RA Extended-spectrum beta-lactamases: A clinical update Clin Microbiol Rev 2005 Oct18 4 657 686 https://doi.org/10.1128/CMR.18.4.657-686.2005126590816223952Open DOISearch in Google Scholar

Ramdani-Bouguessa N, Manageiro V, Jones-Dias D, Ferreira E, Tazir M, Caniça M. Role of SHV β-lactamase variants in resistance of clinical Klebsiella pneumoniae strains to β-lactams in an Algerian hospital. J Med Microbiol. 2011 Jul;60(Pt 7):983–987. https://doi.org/10.1099/jmm.0.030577-0 Ramdani-Bouguessa N Manageiro V Jones-Dias D Ferreira E Tazir M Caniça M Role of SHV β-lactamase variants in resistance of clinical Klebsiella pneumoniae strains to β-lactams in an Algerian hospital J Med Microbiol 2011 Jul60 Pt 7 983 987 https://doi.org/10.1099/jmm.0.030577-0316821621415202Open DOISearch in Google Scholar

Rehman N, Azam S, Ali A, Khan I, Asghar M, Ali M, Waqas M, Ullah F, Sehra GE. Molecular epidemiology of antibiotic-resistant genes and potent inhibitors against TEM, CTX-M-14, CTX-M-15, and SHV-1 proteins of Escherichia coli in district Peshawar, Pakistan. Saudi J Biol Sci. 2021 Nov;28(11):6568–6581. https://doi.org/10.1016/j.sjbs.2021.07.028 Rehman N Azam S Ali A Khan I Asghar M Ali M Waqas M Ullah F Sehra GE Molecular epidemiology of antibiotic-resistant genes and potent inhibitors against TEM, CTX-M-14, CTX-M-15, and SHV-1 proteins of Escherichia coli in district Peshawar, Pakistan Saudi J Biol Sci 2021 Nov28 11 6568 6581 https://doi.org/10.1016/j.sjbs.2021.07.028856900134764772Open DOISearch in Google Scholar

Schechter LM, Creely DP, Garner CD, Shortridge D, Nguyen H, Chen L, Hanson BM, Sodergren E, Weinstock GM, Dunne WM Jr, et al. Extensive gene amplification as a mechanism for piperacillintazobactam resistance in Escherichia coli. mBio. 2018 Apr 24;9(2): e00583-18. https://doi.org/10.1128/mBio.00583-18 Schechter LM Creely DP Garner CD Shortridge D Nguyen H Chen L Hanson BM Sodergren E Weinstock GM Dunne WM Jr et al Extensive gene amplification as a mechanism for piperacillintazobactam resistance in Escherichia coli mBio 2018 Apr 249 2 e00583 18 https://doi.org/10.1128/mBio.00583-18591573129691340Open DOISearch in Google Scholar

Stewart AG, Price EP, Schabacker K, Birikmen M, Harris PNA, Choong K, Subedi S, Sarovich DS. Molecular epidemiology of third-generation cephalosporin-resistant Enterobacteriaceae in Southeast Queensland, Australia. Antimicrob Agents Chemother. 2021 May 18;65(6):e00130-21. https://doi.org/10.1128/AAC.00130-21 Stewart AG Price EP Schabacker K Birikmen M Harris PNA Choong K Subedi S Sarovich DS Molecular epidemiology of third-generation cephalosporin-resistant Enterobacteriaceae in Southeast Queensland, Australia Antimicrob Agents Chemother 2021 May 1865 6 e00130 21 https://doi.org/10.1128/AAC.00130-21831590833781999Open DOISearch in Google Scholar

Sun J, Wang Y, Ni YX. [Hyperproduction of TEM-1 β-lactamase mediates the resistance of Escherichia coli to piperacillin-tazobactam and cefoperazone] (in Chinese). Chin J Infect Chemother. 2013 May;13(3):167–172. https://doi.org/10.16718/j.1009-7708.2013.03.003 Sun J Wang Y Ni YX [Hyperproduction of TEM-1 β-lactamase mediates the resistance of Escherichia coli to piperacillin-tazobactam and cefoperazone] (in Chinese) Chin J Infect Chemother 2013 May13 3 167 172 https://doi.org/10.16718/j.1009-7708.2013.03.003Open DOISearch in Google Scholar

Thomson KS, AbdelGhani S, Snyder JW, Thomson GK. Activity of cefepime-zidebactam against multidrug-resistant (MDR) Gram-Negative pathogens. Antibiotics (Basel). 2019 Mar 23;8(1):32. https://doi.org/10.3390/antibiotics8010032 Thomson KS AbdelGhani S Snyder JW Thomson GK Activity of cefepime-zidebactam against multidrug-resistant (MDR) Gram-Negative pathogens Antibiotics (Basel) 2019 Mar 238 1 32 https://doi.org/10.3390/antibiotics8010032646658630909535Open DOISearch in Google Scholar

Tian X, Wang Q, Perlaza-Jiménez L, Zheng X, Zhao Y, Dhanasekaran V, Fang R, Li J, Wang C, Liu H, Lithgow T, Cao J, Zhou T. First description of antimicrobial resistance in carbapenem-susceptible Klebsiella pneumoniae after imipenem treatment, driven by outer membrane remodeling. BMC Microbiol. 2020 Jul 20;20(1):218. https://doi.org/10.1186/s12866-020-01898-1 Tian X Wang Q Perlaza-Jiménez L Zheng X Zhao Y Dhanasekaran V Fang R Li J Wang C Liu H Lithgow T Cao J Zhou T First description of antimicrobial resistance in carbapenem-susceptible Klebsiella pneumoniae after imipenem treatment, driven by outer membrane remodeling BMC Microbiol 2020 Jul 2020 1 218 https://doi.org/10.1186/s12866-020-01898-1737280732689945Open DOISearch in Google Scholar

Winkler ML, Papp-Wallace KM, Taracila MA, Bonomo RA. Avibactam and inhibitor-resistant SHV β-lactamases. Antimicrob Agents Chemother. 2015 Jul;59(7):3700–3709. https://doi.org/10.1128/AAC.04405-14 Winkler ML Papp-Wallace KM Taracila MA Bonomo RA Avibactam and inhibitor-resistant SHV β-lactamases Antimicrob Agents Chemother 2015 Jul59 7 3700 3709 https://doi.org/10.1128/AAC.04405-14446874125691639Open DOISearch in Google Scholar

Zhou K, Tao Y, Han L, Ni Y, Sun J. Piperacillin-tazobactam (TZP) resistance in Escherichia coli due to hyperproduction of TEM-1 β-Lactamase mediated by the promoter Pa/Pb. Front Microbiol. 2019 Apr 16;10:833. https://doi.org/10.3389/fmicb.2019.00833 Zhou K Tao Y Han L Ni Y Sun J Piperacillin-tazobactam (TZP) resistance in Escherichia coli due to hyperproduction of TEM-1 β-Lactamase mediated by the promoter Pa/Pb Front Microbiol 2019 Apr 1610833 https://doi.org/10.3389/fmicb.2019.00833647696731040841Open DOISearch in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo